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Summary  Uric  acid  is  the  end  product  of  purine  metabolism.  Its  immediate  precursor,  xan-
thine, is  converted  to  uric  acid  by  an  enzymatic  reaction  involving  xanthine  oxidoreductase.
Uric acid  has  been  formerly  considered  a  major  antioxidant  in  human  plasma  with  possible  ben-
eﬁcial anti-atherosclerotic  effects.  In  contrast,  studies  in  the  past  two  decades  have  reported
associations  between  elevated  serum  uric  acid  levels  and  cardiovascular  events,  suggesting  a
potential role  for  uric  acid  as  a  risk  factor  for  atherosclerosis  and  related  diseases.  In  this
paper, the  molecular  pattern  of  uric  acid  formation,  its  possible  deleterious  effects,  as  well  as
the involvement  of  xanthine  oxidoreductase  in  reactive  oxygen  species  generation  are  critically
discussed.  Reactive  oxygen  species  contribute  to  vascular  oxidative  stress  and  endothelial  dys-
function, which  are  associated  with  the  risk  of  atherosclerosis.  Recent  studies  have  renewed
attention  to  the  xanthine  oxidoreductase  system,  since  xanthine  oxidoreductase  inhibitors,  such
as allopurinol  and  oxypurinol,  would  be  capable  of  preventing  atherosclerosis  progression  by
reducing endothelial  dysfunction.  Also,  beneﬁcial  effects  could  be  obtained  in  patients  with
congestive  heart  failure.  The  simultaneous  reduction  in  uric  acid  levels  might  contribute  to
these effects,  or  be  a  mere  epiphenomenon  of  the  drug  action.  The  molecular  mechanisms
involved are  discussed.
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ntroduction
t  has  been  hypothesized  that  uric  acid  (UA)  provides  an
ntioxidant  defense  in  humans,  so  that  it  might  be  protec-
ive  against  oxidative  stress  in  cardiac,  vascular,  and  neural
ells  [1—3]. In  contrast,  several  studies  in  the  past  two
ecades  have  suggested  that  elevated  serum  UA  (SUA)  levels
re  associated  with  cardiovascular  diseases  [4,5]. For  exam-
le,  Neogi  et  al.  [6]  found  that  SUA  is  not  associated  with
oronary  artery  calciﬁcation,  a  known  marker  for  early  pre-
linical  coronary  artery  disease  (CAD)  but,  on  the  contrary,
rishnan  et  al.  [7]  recently  showed  that,  after  adjustment
or  many  confounding  factors,  elevated  SUA  levels  corre-
ated  with  the  presence  and  severity  of  coronary  artery
alciﬁcation  in  a  cohort  of  young  healthy  adults.  Thus,  the
uestion  arises  whether  the  known  antioxidant  UA  exerts
rotective  vascular  effects,  or  is  a  risk  factor  for  cardiovas-
ular  diseases.  The  aim  of  this  paper  is  to  critically  review
he  paradoxical  association  between  the  antioxidant  UA  and
ncreased  cardiovascular  morbidity  and  mortality.  Moreover,
he  molecular  aspects  of  UA  formation  and  its  potential  role
n  vascular  oxidative  stress  are  described.
he role of  xanthine oxidoreductase in
ndothelial dysfunction
anthine  oxidoreductase  (XOR)  is  a  molybdoﬂavoprotein
nzyme  that  exists  in  two  interconvertible  functionally
istinct  forms,  namely  xanthine  dehydrogenase  (XD)  and
anthine  oxidase  (XO)  (Fig.  1).  XO  is  generated  from  XD  by
roteolysis  and  catalyzes  the  two  terminal  steps  of  purine
egradation  (hypoxanthine  →  xanthine  →  UA)  in  humans.  By
xidation  of  hypoxanthine  to  xanthine,  and  xanthine  to
rate  [8—13], XO  readily  donates  electrons  to  molecular
xygen,  thereby  producing  superoxide  radical  (O2−) and
ydrogen  peroxide.Both  XD  and  XO  contain  an  internal  elec-
ron  transport  system  that  is  capable  of  producing  reactive
xygen  species  (ROS)  [14—16]. The  physiological  substrates,
anthine  and  hypoxanthine,  bind  the  oxidized  enzyme  and
onate  two  electrons  to  the  molybdenum  cofactor,  reduc-
ng  it  from  MoVI to  MoIV.  Substrates  are  hydroxylated  by
2O  at  the  molybdenum  site  as  the  electrons  travel  via
wo  iron-sulﬁde  residues  to  ﬂavine-adenine  oligonucleotide
FAD).  Reduced  FAD  can  be  divalently  reoxidized  by  oxygen
o  produce  hydrogen  peroxide,  or  univalently  reoxidized  in
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Figure  1  Main  reactions  involving  uric  acid  and  reactive  oxy-
gen species  (see  text).  NO,  nitric  oxide;  O2−,  superoxide  anion;
OONO−,  peroxynitrite;  XD,  xanthine  dehydrogenase;  XO,  xan-
thine oxidase.
produced  by  either  XO  or  XD  can  bind  nitric  oxide  (NO)  to
form  peroxynitrite  (OONO−),  a  potent  non-radical  oxidant
species  [24]. NO  is  usually  generated  by  NO  synthase  (NOS),
although  XOR  may  also  be  a  contributory  source  of  NO  under
hypoxic  conditions  [25,26]. Since  endothelium-derived  NO
controls  vascular  tone,  prevents  adhesion  of  leukocytes,
inhibits  aggregation  and  adhesion  of  platelets,  and  reduces
intima  proliferation,  the  reduction  of  NO  bioavailability
induces  endothelial  dysfunction  and  oxidative  stress,  a  key
mechanism  of  vascular  risk  and  dysfunction.Endothelial  dys-
function  can  be  induced  by  all  common  cardiovascular  risk
factors,  which  are  able  to  activate  many  enzymatic  systems
(such  as  XO,  NADPH  oxidase,  uncoupled  eNOS  and  mito-
chondrial  respiratory  chain)  thus  favoring  ROS  generation.
In  particular,  XO  has  been  implicated  as  a source  of  ROS  in
the  vascular  system.
Uric acid as a potentially useful antioxidant
UA,  together  with  ascorbic  acid,  is  considered  a  major
water  soluble  intracellular  free  radical  scavenger,  as  well
as  an  antioxidant  in  human  plasma  [3,27], since  it  can  reactwo  steps  to  generate  two  equivalents  of  superoxide  rad-
cal  [12,14,17—19].Superoxide  has  been  identiﬁed  as  the
ost  probable  ROS  contributing  to  cardiac  dysfunction  in
he  failing  myocardium  [12,20—23].  The  superoxide  radical
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sith  superoxide  anion,  hydrogen  peroxide,  hydroxyl  radical,
nd  particularly  peroxynitrite.  UA  reacts  preferentially  with
eroxynitrite  anion  [28,29], which  is  a  short-lived  oxidant
pecies  formed  by  the  reaction  between  NO  and  superoxide
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radical,  occurring  particularly  in  the  vascular  endothelium
(Fig.  1).
Peroxynitrite  is  capable  of  inducing  cell  death  or  abnor-
mal  functioning  [30], thus  contributing  to  various  forms
of  cardiovascular  diseases  [31—37]. In  cell  culture  systems
peroxynitrite  induced  tetrahydrobiopterin  oxidation  and  a
decrease  in  NO  generation  [28,37].  The  addition  of  UA  could
prevent  oxidative  damage  in  part  by  restoring  NO  genera-
tion,  and  in  part  contributing  to  maintain  extracellular  levels
of  superoxide  dismutase  (EC-SOD),  the  only  antioxidant
enzyme  capable  of  scavenging  superoxide  anion  [38,39].
In  peroxynitrite-treated  human  plasma,  Skinner  et  al.
[40]  have  detected  a  nitrated  UA  derivative.  This  prod-
uct  may  be  involved  in  human  pathophysiology  by  releasing
NO,  which  could  decrease  vascular  tone  and  increase  tissue
blood  ﬂow,  thereby  suggesting  a  novel  beneﬁcial  role  for
UA.  The  relationship  between  UA  and  NO  has  been  further
clariﬁed  by  the  characterization  of  another  reactive  prod-
uct  of  UA  with  NO  under  aerobic  conditions  [41]. By  mass
spectrometric  data  this  product  was  identiﬁed  as  nitrosated
UA,  which  results  from  the  reaction  with  NO  donors,  but
not  with  peroxynitrite.  Thus  UA  may  act  as  a  vehicle  of  NO,
suggesting  that  its  elevated  levels  may  represent  a favor-
able  response  to  oxidative  stress  in  cardiovascular  diseases
[3,42].
Deleterious effects of uric  acid and
mechanisms involved
In  overt  contrast  with  the  above  data,  since  2005  exper-
imental  and  clinical  studies  have  suggested  that  elevated
UA  levels  are  associated  with  a  reduction  in  NO  levels
with  ensuing  endothelial  dysfunction.  UA  reduces  NO  lev-
els  in  endothelial  cell  cultures,  blocks  acetylcholine-induced
vasodilatation  of  aortic  rings,  and  reduces  circulating
nitrites  in  experimental  animals  [43]. Further,  rat  studies
have  shown  that  hyperuricemia-induced  hypertension  and
vascular  disease  are  partially  reversed  by  the  supplemen-
tation  of  the  NOS  substrate,  L-arginine  [44]. Gersch  et  al.
[45]  have  demonstrated  that  UA  reacts  directly  with  NO  in
a  rapid  irreversible  reaction  resulting  in  the  formation  of  6-
aminouracil,  with  consequent  depletion  of  NO  (Fig.  1).  This
reaction  occurs  preferentially  with  NO,  even  in  the  presence
of  peroxynitrite  and  hydrogen  peroxide.  The  reaction  is  at
least  partially  blocked  by  glutathione,  showing  a  potential
mechanism  by  which  UA  could  deplete  NO  under  condi-
tions  of  oxidative  stress,  when  intracellular  glutathione  is
depleted.
The  complexity  of  the  reactions  of  UA  with  peroxyni-
trite  has  recently  been  described  by  Gersch  et  al.  [46]  and
Imaram  et  al.  [47]. UA  can  decompose  and  generate  free
radicals  in  various  reactions  [47], including  the  reaction  with
peroxynitrite  [48—50]. One  such  radical  has  been  identi-
ﬁed  as  the  aminocarbonyl  radical  [50], derived  from  the
intermediate  triuretcarbonyl  radical,  which  in  turn  could
be  an  intermediate  candidate  for  the  generation  of  triuret
[51,52].  In  addition,  in  this  reaction  UA  can  generate  alky-
lated  products  and  allantoin.  Thus,  the  studies  of  the  Gersch
group  [45,46]  suggest  a  further  potential  pathway  by  which
the  UA-peroxynitrite  reaction  might  lead  to  deleterious
pro-oxidative  effects  mediated  by  the  formation  of  reactive
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ntermediates  capable  of  alkylating  biomolecules  containing
H,  labile  hydrogens,  or  reactive  functional  groups.  These
ffects  can  be  partially  prevented  by  ascorbate  [45].
In community-dwelling  older  persons,  signiﬁcant  associa-
ions  have  been  shown  between  SUA  levels  and  inﬂammatory
arkers,  such  as  white  blood  cells,  C-reactive  protein,
nterleukin-1  (IL-1),  IL-6,  IL-6  receptor,  IL-10,  IL-18,  and
umor  necrosis  factor-alpha  [53], suggesting  that  UA  might
ontribute  to  the  pro-inﬂammatory  state  of  several  chronic
onditions  typically  affecting  the  old  [54]. It  has  also  been
roposed  that  changes  in  the  expression  of  endothelin-1  are
nother  mechanism  by  which  hyperuricemia  might  favor  car-
iovascular  diseases  [55,56].  Moreover,  UA  can  act  as  an
ndogenous  danger  signal  capable  of  stimulating  the  innate
mmune  response  [57], and  it  is  well  known  that  the  immune
esponse  plays  a  role  in  the  development  of  hypertension,
enal,  and  cardiovascular  diseases  [58]. Finally,  in  vitro
tudies  with  vascular  smooth  muscle  cells  have  shown  that
ncubation  with  UA  stimulates  cell  proliferation,  angiotensin
I  production  and,  oxidative  stress.  These  changes  were
eversed  by  the  addition  of  captopril  or  losartan,  which
uggests  an  effect  mediated,  at  least  in  part,  by  the  renin-
ngiotensin  system  [59]. Moreover,  smooth  muscle  cells  of
uman  aorta  express  URAT1,  a  urate  transporter,  on  their
ell  membrane  [60], indicating  a  speciﬁc  functional  role  for
A  in  these  cells.
The  above  experimental  ﬁndings  led  to  renewed  interest
n  the  possible  role  of  UA  in  the  pathogenesis  of  vascular
iseases  [61].
ric acid as a risk factor for vascular disease
lthough  many  experimental  and  epidemiological  data  have
uggested  a  possible  role  for  hyperuricemia  in  induc-
ng  endothelial  dysfunction,  and  particularly  impaired  NO
ioavailability,  not  all  studies  have  shown  a  causal  role
or  UA  in  the  development  of  coronary  heart  disease  or
eath  from  cardiovascular  causes.  Mankovsky  et  al.  [62]
ave  extensively  reviewed  numerous  publications  of  the  past
wo  decades,  many  epidemiological,  concerning  the  pos-
ible  relationship  between  SUA  levels  and  cardiovascular
isorders,  such  as  CAD,  stroke,  hypertension,  and  metabolic
yndrome.  The  relation  between  SUA  and  cardiovascular
isease  was  observed  not  only  with  frank  hyperuricemia
deﬁned  as  more  than  6  mg/dl  in  women  and  7  mg/dl  in
en),  but  also  with  SUA  levels  in  the  normal  to  high  range
5.2—6  mg/dl)  [63—68]. Raised  levels  of  SUA,  together  with
igh-sensitivity  troponin  T  and  N-terminal  pro-B-type  natri-
retic  peptide,  have  been  found  in  most  patients  with
ssential  hypertension  [69]. In  patients  with  chronic  heart
ailure,  hyperuricemia  is  associated  with  high  cardiac  event
ates  [70]  and,  in  combination  with  six  other  conventional
iomarkers,  it  may  contribute  to  risk  stratiﬁcation  [71].
ecently  Neogi  et  al.  [72]  have  assessed  the  association
f  SUA  with  carotid  plaques  in  a  large  multicenter  study,
he  NHLBI  Family  Heart  Study.  SUA  was  found  to  be  asso-
iated  with  carotid  plaques  in  men,  even  in  the  absence
f  other  cardiovascular  risk  factors.  However,  analyzing  the
ame  data  set  [6],  the  authors  were  unable  to  demonstrate
ny  association  of  SUA  with  coronary  artery  calciﬁcations,  a
nown  marker  for  early  preclinical  CAD  (in  contrast  with  the
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ndings  of  Krishnan  et  al.  [7]).  In  1901  consecutive  patients
ndergoing  coronary  angiography,  De  Luca  et  al.  [73]  showed
hat  UA  was  not  associated  with  the  extent  of  CAD  and  the
ntima-media  thickness  of  carotid  arteries.  Similarly,  several
ther  studies  did  not  ﬁnd  any  association  between  raised  SUA
evels  and  cardiovascular  events  [74—78].
Thus,  the  possible  signiﬁcance  of  hyperuricemia  is  still
idely  debated.  It  remains  unsolved  whether  UA  is  a  causal,
ompensatory,  or  coincidental  factor  [79]. The  difﬁculty  in
scertaining  the  role  of  UA  as  an  independent  risk  factor  for
therosclerosis  is  due  to  the  complex  associations  between
yperuricemia  and  conventional  risk  factors.  A  systematic
eview  with  meta-analysis  of  26  prospective  cohort  studies
80]  has  shown  a  modest  but  signiﬁcant  association  between
yperuricemia  and  CAD  events,  independent  of  traditional
isk  factors.  The  overall  risk  of  CAD  death  increased  by  12%
or  each  increase  of  1  mg/dl  SUA,  although  hyperuricemia
ppeared  to  signiﬁcantly  increase  the  risk  of  death  only
n  women.  This  gender  difference  should  be  conﬁrmed  by
uture  research.
It  is  well  known  that  patients  with  gout  and  hyper-
ricemia  frequently  experience  several  comorbidities,  such
s  hypertension,  chronic  kidney  disease,  insulin  resistance,
nd  obesity,  which  complicate  management  and  affect  long-
erm  prognosis  [81]. The  extent  to  which  hyperuricemia  and
out  may  be  either  a  cause  or  a  consequence  of  these  con-
itions  is  still  debated.  Further  research  should  also  clarify
his  important  question.
otential beneﬁts of xanthine oxidase
nhibition  in the management of
ardiovascular risk
acher  et  al.  [82]  have  reviewed  both  the  molecular  bio-
hemistry  of  XOR  and  the  effects  of  XO  inhibitors  in  various
athophysiological  conditions  such  as  gout,  stroke,  circula-
ory  shock,  global  heart  failure,  and  ischemia-reperfusion
njury  of  the  myocardium,  liver,  kidney,  and  lungs.  The
utative  use  of  XO  inhibitors  in  the  treatment  of  hyperten-
ion,  hypercholesterolemia,  atherosclerosis,  and  diabetes
as  also  been  discussed  [82]. In  particular,  recent  rele-
ant  clinical  research  has  focused  on  the  use  of  the  XO
nhibitors  allopurinol  and  oxypurinol  in  the  prevention  of
ardiovascular  disease.  Allopurinol  is  a  structural  analogue
f  hypoxanthine  and  is  quickly  metabolized  to  oxypurinol
hich,  similarly  to  allopurinol,  can  bind  XO  and  inhibit  its
ctivity.  Febuxostat,  a  non-purine  XO-speciﬁc  inhibitor,  is
eported  to  be  signiﬁcantly  more  potent  than  allopurinol
83], which  shows  that  a  xanthine-like  structural  framework
s  not  a  prerequisite  for  high  XO  inhibitory  activity.
Allopurinol  has  been  found  to  improve  endothelial  func-
ion  in  type  2  diabetes  [84], in  hyperuricemic  patients
ith  chronic  heart  failure  [85], and  in  heavy  smokers
86].  In  2006,  George  et  al.  [87]  showed  that  a  steep
ose—response  relationship  exists  between  allopurinol  and
ts  effects  on  endothelial  dysfunction  in  patients  with
hronic  heart  failure  (New  York  Heart  Association  class
I—III):  high-dose  allopurinol  (600  mg/dl)  totally  abolished
he  oxidative  stress,  independently  of  urate  reduction.
hese  data  were  partially  contradicted  by  the  study  of  Gal-
usera  et  al.  [14], which  showed  that  allopurinol  in  vitro
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enerated  superoxide  radicals  during  its  conversion  to  oxy-
urinol,  whereas  oxypurinol  did  not  produce  superoxide.
owever,  it  would  be  difﬁcult  to  speculate  on  how  much
uperoxide  would  be  produced  in  vivo, and  whether  the
uperoxide  generated  from  allopurinol  contributes  to  oxida-
ive  stress  and  tissue  pathology.  Anyway,  oxypurinol  seems  to
e  more  effective  than  allopurinol  as  an  inhibitor  of  superox-
de  production  [88]. Hare  et  al.  [89]  have  studied  the  effects
f  oxypurinol  in  a  cohort  of  patients  with  symptomatic
eart  failure  (class  III—IV  New  York  Heart  Association)  and
eft  ventricular  dysfunction  receiving  optimal  medical  ther-
py.  Oxypurinol  did  not  produce  clinical  improvements  in
nselected  patients  with  moderate-to-severe  heart  failure.
owever,  patients  with  high  SUA  levels  might  beneﬁt  from
O  inhibition.  In  fact,  the  degree  of  SUA  reduction  corre-
ated  with  clinical  outcome,  and  the  patients  that  worsened
ad  a  relatively  smaller  reduction  in  SUA  levels.  The  authors
oncluded  that  SUA  may  serve  as  a  valuable  biomarker  to
arget  XO  inhibition  in  patients  with  congestive  heart  fail-
re.  Similarly,  according  to  Wu  et  al.  [90]  elevated  SUA
evels  could  be  an  independent  predictor  of  mortality  in
atients  with  severe  heart  failure.  On  the  other  hand,  in
atients  with  nonelevated  SUA  and  ischemic  cardiomyopa-
hy  with  severely  suppressed  systolic  function,  Baldus  et  al.
91]  found  that  a  single  intravenous  dose  of  oxypurinol
400  mg)  improved  myocardial  contractility,  while  benzbro-
arone  [92], a  uricosuric  agent  that  does  not  inhibit  XO,
id  not  affect  brain  natriuretic  peptide  and  left  ventricu-
ar  ejection  fraction  in  patients  with  chronic  heart  failure,
lthough  fasting  insulin  and  insulin  resistance  improved.
Overall,  these  data  underscore  the  role  of  ROS  as  key
ediators  of  ischemic  heart  failure,  the  signiﬁcance  of  XO
s  a  source  of  ROS  and  the  beneﬁcial  effects  of  XO  inhibitors,
ut  they  would  also  show  that  elevated  SUA  levels  may  not
e  directly  associated  with  myocardial  impairment.  In  fact
here  are  studies  showing  that  SUA  has  no  causal  relation-
hip  with  cardiovascular  diseases,  so  that  a  reduction  in  its
evels  would  play  no  role  in  preventing  them  but,  on  the
ther  hand,  other  studies  suggest  that  elevated  SUA  lev-
ls  may  be  a  marker  of  the  risk  for  the  development  of
uch  conditions  [67,93—95].  These  conﬂicting  results  have
een  widely  discussed  [82,95,96]  and,  based  on  the  pre-
onderance  of  recent  epidemiologic  studies,  it  appears  that
levated  SUA  may  be  at  least  an  independent  predictor  of
he  risk  of  kidney  disease,  hypertension,  and  cardiovascular
isease,  including  acute  myocardial  infarction  [66,68,97].
Thus,  the  beneﬁcial  effects  of  XO  inhibitors  might  be
elated  to  decreased  ROS  production,  SUA  reduction,  or
oth.  Certainly  more  studies  in  this  interesting  area  of
esearch  are  needed  to  fully  elucidate  the  complex  mech-
nisms  connecting  XO  inhibitors  with  the  prevention  and
herapy  for  cardiovascular  diseases.
onclusions
ome  studies  have  shown  an  association  between  SUA  lev-
ls  and  subsequent  development  of  hypertension  [98—100].
oreover,  an  association  between  SUA  levels  and  surrogate
arkers  of  atherosclerosis  is  starting  to  emerge  [101—103],
nd  associations  with  hard  atherosclerosis  clinical  endpoints
ave  also  been  described  [104—109].  However,  the  role  of
Uric  acid  involvement  in  cardiovascular  diseases  
UA  as  an  independent  risk  factor  for  cardiovascular  events
is  still  debated  [110,111].  Manzato  [112]  suggested  that,  in
the  presence  of  elevated  SUA  levels,  other  factors,  such  as
insulin  resistance,  glucose  intolerance,  dyslipidemia,  hyper-
tension,  use  of  diuretics,  and  obesity,  may  play  the  true
causal  role  in  increasing  vascular  risk.  The  apparent  ben-
eﬁcial  role  of  XO  inhibitors  could  be  due  to  their  ability
to  consistently  improve  endothelial  dysfunction  by  reduc-
ing  oxidative  stress,  rather  than  to  urate  reduction.  Finally,
the  precise  mechanism  for  UA-induced  tissue  injury  remains
unclear,  even  if  UA  might  play  a  role  in  oxidative  stress,  in
the  formation  of  ROS  and,  consequently,  in  the  impairment
of  NO  production.  To  date  no  large  blinded,  randomized,
placebo-controlled  studies  have  clearly  demonstrated  that
lowering  SUA  can  prevent  or  lessen  the  risk  of  cardiovascu-
lar  disease,  renal  disease,  diabetes,  or  hypertension,  even
though  they  may  correlate  with  hyperuricemia.  Future  large
clinical  studies  will  have  to  ascertain  whether  XO  inhibition
and/or  UA  reduction  are  able  to  deliver  long-term  beneﬁts,
as  smaller  studies  suggest  they  might.
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